alzheimer News
-
A night at Sardi`s announces 2011 Honoree
The 19th Annual "A Night at Sardi's," a star-studded benefit for the Alzheimer's Association on Wednesday, March 16, 2011 at the Beverly Hilton, will honor The Walt Disney Company's President and CEO Robert A. Iger for his contributions in the fight against Alzheimer's disease. Mr. Iger will receive the Abe Burrows Entertainment Award, which is presented to an individual who has shown an ...
-
AFR: NeuroScientific targets Alzheimer’s cure
NeuroScientifc Biopharmaceuticals says the $5 million it's seeking to raise will fast track the development of an Alzheimer's treatment that the biotech reckons could be "one of the greatest drugs ever". ...
-
Putting Alzheimer’s on early notice
The International Conference on Alzheimer"s disease in Hawaii heard that scientists from the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) have identified advances in imaging and blood screening that will contribute to the earlier detection of Alzheimer’s. About 250,000 Australians currently have Alzheimer’s disease, but numbers are anticipated to rise ...
-
OBD selected to talk at AD/PD 2022 Conference
Oxford Brain Diagnostics team are really looking foward to attending ADPD2022 this year. We invite all our colleagues, friends and collaborators to listen into our talk. Its starts at 18:45 (CET) 17th March 2022. - 'Novel in vivo cortical diffusion MRI measures correlate with classical neuropathology across the #alzheimers continuum in an autopsy confirmed ...
-
MetLife Foundation announces results of its 2010 thanksgiving charitable program
MetLife Foundation today announced the results of its first ever Thanksgiving charitable program. Fans of the New York Jets and New York Giants, voting at the New Meadowlands Stadium, and members of the general public, voting online at www.MetLife.com/thanksgiving helped to determine how a special half-million dollar donation will be shared among four charities. The organizations who will be ...
-
Alzheimer’s protein puts top brains to the test
Alzheimer’s disease is one of the fastest growing diseases in Australia and the most common form of dementia. The number of people with dementia is expected to rise from 300,000 to 1.13 million by 2050. Alzheimer’s disease is associated with the development of a toxic protein in the brain known as amyloid beta. The amyloid beta protein rapidly self-assembles in the brain and builds ...
-
Patent Issues for Novel Huntington`s and Alzheimer`s Disease Gene Therapy
Vybion announces the issue by the USPTO of Patent No. 9932394 entitled, "Single Chain Intrabodies that Alter Huntingtin Mutant Degradation". Issued claims cover composition of matter as well as both the Huntingtin and Tau protein targets with the potential for treatment of both Huntington's and Alzheimer's diseases. A continuation on the remaining methods claims has been filed. This patent ...
By Vybion
-
DiamiR Announces Oral Presentation at 21st International Conference on Alzheimer`s Drug Discovery
DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, today announced that Dr. Kira Sheinerman, Chief Executive Officer, will be presenting and participating in a panel discussion at The 21st International Conference on Alzheimer's Drug Discovery hosted by the Alzheimer's Drug Discovery Foundation (ADDF) and held virtually October 5-6, ...
By DiamiR
-
Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease
Optos Plc, a subsidiary of Nikon Corporation, Japan, and Amydis, Inc. today announced a clinical alliance focused on the development of an eye test by Amydis to detect Alzheimer’s disease. Amydis has developed a pipeline of compounds to detect amyloid proteins in the retina to be visualized with Optos’ market-leading optomap ultra-widefield retinal imaging devices to diagnose ...
By Optos, Inc.
-
MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner Roche (SIX: RO, ROG; OTCQX: RHHBY) provided an update on the GRADUATE I and II studies evaluating gantenerumab in people with early Alzheimer’s disease (AD). The studies did not meet their primary endpoint of slowing clinical decline. The level of beta-amyloid removal, the protein that builds up to make plaques ...
By MorphoSys AG
-
MetLife Foundation announces its 2010 thanksgiving charity program
MetLife Foundation today announced its first-ever Thanksgiving charity program, kicking off on Sunday, November 21. Fans of the New York Jets and New York Giants, and members of the general public, will have the opportunity to actively participate and make a real difference by helping to determine how a special half-million dollar gift will be shared among four charities. Selections can be made ...
-
An Israeli Scientist Paves the Way to Alzheimer’s Cure, One Algorithm at a Time
Calcalist – Yedioth Ahronoth had a thorough and fascinating interview with Shahar Barbash (CEO) and Michael Levitt (Board of Directors). Read it here in Hebrew. The interview was also translated into English and published here in The Algemeiner. ...
-
Novatek to support hope for Dementia Charity Gala Jan. 31, 2019
We are SO EXCITED to support the first Charity Gala for Hope for Dementia that will take place on January 31, 2019 in Montreal, QC! Join us for an unforgettable evening of Live Entertainment, Dignitary Speeches from Local & Community Leaders and Touching Story-Telling to support Hope for Dementia! Hope for Dementia is a non-profit organization working to support the cause of safeguarding ...
-
Metlife foundation announces major awards to scientists for research in alzheimer`s disease
The 25th anniversary presentation of the MetLife Foundation Awards for Medical Research in Alzheimer's Disease (AD) was held today honoring two noted researchers, Randy L. Buckner, Ph.D., professor of Psychology and of Neuroscience at Harvard University and Howard Hughes Medical Institute Investigator, and Marcus E. Raichle, M.D., professor of radiology and neurology at Washington University ...
-
Lilly`s donanemab slowed Alzheimer`s disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM
Phase 2 TRAILBLAZER-ALZ results presented today by Eli Lilly and Company (NYSE: LLY) at the 15th International Conference on Alzheimer's & Parkinson Diseases™ 2021 (AD/PD™ 2021) held virtually March 9-14, 2021 and published simultaneously in the New England Journal of Medicine (NEJM) expand on previously reported top-line data that found donanemab met its primary endpoint and ...
-
Optina Diagnostics Receives Breakthrough Device Designation from U.S. FDA for a Retinal Imaging Platform to Aid in the Diagnosis of Alzheimer’s Disease
Optina Diagnostics announces today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its retinal imaging platform (CAPRS1/MHRC2). Optina Diagnostics’ platform uses Artificial Intelligence (AI) to analyze the data rich hyperspectral retinal images captured with the MHRC during a simple eye scan. Optina Diagnostics’ platform is intended for ...
-
Celdara Medical Announces Funding for Alzheimer’s-Focused Fellowship Opportunities
Celdara Medical, LLC today announced that the National Institute of Aging’s Research and Entrepreneurial Development Immersion (REDI) initiative has awarded an R25 Entrepreneurship Enhancement Award to fund the company’s comprehensive training program focused on Alzheimer’s Disease: the Alzheimer’s-focused Celdara Medical High-Potential Entrepreneurs’ Fellowship ...
-
Oxford Brain Diagnostics awarded FDA Breakthrough Device Designation for technology to predict Alzheimer’s Disease
Oxford Brain Diagnostics Ltd, a spinout from the University of Oxford specialising in the measurement of neurodegeneration in Alzheimer’s disease, today announces that the US Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its Cortical Disarray Measurement (CDM®) Software Device for evaluating adults at risk of Alzheimer’s disease Oxford Brain ...
-
Qynapse to Sponsor and Present New Data on QyPredict at Clinical Trials on Alzheimer’s Disease Conference (CTAD 2021)
BOSTON, MA, November 4, 2021, PRNewswire – Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to sponsor the 14th Clinical Trials on Alzheimer’s Disease conference (CTAD) to be held from November 9-12, 2021, in Boston, MA. Qynapse will present new results on Qypredict®, ...
By Qynapse
-
CPAD - Critical Path for Alzheimer`s Disease
OBD becomes a member of the CPAD Initiative. This consortium works with industry, regulatory authorities, and patient advocacy organisations to advance Drug Development Tools (DDTs) for evaluating drug efficacy and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you